Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comparative Effectiveness News In Brief

Executive Summary

AHRQ updating CER report on off-label atypical antipsychotic use: The Agency for Healthcare Research and Quality is performing a routine update to its Jan. 17, 2007, comparative effectiveness 1review of the off-label use of atypical antipsychotics. The agency, in a comment request on its 2Web site, notes that since the original report was published, "some important changes have occurred and part of the conclusions of the original report might be out of date." Among the changes highlighted are the availability of new studies, including randomized control trials, that have provided more efficacy evidence on off-label use of atypicals; new off-label uses have been identified; previous off-label uses have become approved uses; and new or increased adverse effects of off-label indications have been observed. Comments are being accepted until Feb. 9

You may also be interested in...



Comparative Effectiveness Language Clarified In Compromise Stimulus Bill

Congress took steps in its final version of the economic stimulus package to alleviate concerns that the comparative effectiveness research provisions will lead to the government making cost-based comparisons or making coverage and reimbursement decisions based on the research

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel